Yearly STL Archives: 2023

Risankizumab in Adults with Psoriatic Arthritis

Explore risankizumab for Psoriatic arthritis: Beyond ACR, it significantly improves enthesitis, dactylitis, and QoL scores like HAQ-DI. Promising in efficacy and safety, with full 208-week study results anticipated for a complete understanding.

Dupilumab for the Treatment of Prurigo Nodularis

Dupilumab: A groundbreaking FDA and Health Canada-approved treatment for Prurigo Nodularis (PN). This innovative therapy targets IL-4 and IL-13 signalling, effectively reducing inflammation, pruritus, and lesions. Its approval marks a paradigm shift in PN management, offering new hope for patients.

Update on Drugs & Devices: November-December 2023

Update on Bimekizumab-bkzx for SC injection (Bimzelx®), Clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%fixed-dose topical gel (Cabtreo™), Roflumilast cream 0.3% (Zoryve®), Nivolumab for IV use (Opdivo®), Secukinumab for IV use (Cosentyx®)

Topical Roflumilast for Plaque Psoriasis

Targeting PDE4 with the selective inhibitor roflumilast, specifically through topical cream at a concentration of 0.3%, has proven to be an effective and well-tolerated strategy for treating plaque psoriasis.

A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology

This guide will help you navigate the benefits of recent advancements in topical drug formulations and delivery systems. These innovations address limitations seen in older formulations, ensuring efficient and uniform delivery of active ingredients to target areas, improving patient acceptability, and enhancing treatment outcomes.

Update on Drugs & Devices: September-October 2023

Update on Cantharidin topical solution 0.7% (Ycanth™), Ritlecitinib capsules (Litfulo™), Clascoterone cream 1% (Winlevi®), and Isotretinoin capsules micronized formulation (Absorica LD®).

Casmo Prevention and Management of Four Common Cutaneous Toxicities Associated with Targeted Cancer Therapies: Papulopustular Eruption, Xerosis, Paronychia, and...

Advances in cancer treatment have contributed to a reduction in mortality but survivors and healthcare providers should be aware of the potential adverse effects of these advanced treatments.

Managing Psoriasis with Topical Agents – Where Do We Stand?

Psoriasis vulgaris is a chronic, immune-mediated inflammatory skin disease affecting 2-4% of the Canadian population. While most psoriasis vulgaris cases are mild-to-moderate (>80%) and do not require systemic treatment, these cases can still be particularly challenging to treat as topical therapies present limitations, including efficacy and administration, leading to poor long-term treatment compliance and unsatisfactory treatment responses. The intent of this paper is to provide physicians with a clinically relevant review of the currently available and newly developed topical therapies...

DaxibotulinumtoxinA-lanm (Daxxify™): A Comprehensive Overview

DAXI's innovative biochemical composition, replacing HSA with the peptide RTP004, enhances its efficacy, safety, and duration, potentially using less core neurotoxin, positioning it as a groundbreaking botulinum toxin A (BoNTA) for dynamic facial lines treatment.

Prevention of Shingles in Dermatology Patients on Systemic Medications

Dermatologists should be proactive in recommending RZV to all patients over age 50 years, particularly those with a family history of zoster and diseases with altered immune function. Adult patients who are immunocompromised because of their diseases or treatment (e.g., systemic steroids, JAK inhibitors, combination biologic/conventional disease-modifying antirheumatics), should also be encouraged.

Update on Drugs & Devices: July – August 2023

Update on Roflumilast cream 0.3% (Zoryve™), Adalimumab-aaty SC use (Yuflyma®), Beremagene geperpavec-svdt topical gene therapy (Vyjuvek™), Molecular imaging device (Orlucent®), Tirbanibulin ointment 1% w/w (Onakta™), Pegunigalsidase alfaiwxj for IV use (Elfabrio®), Autologous cell harvesting device (Recell® System), and Odevixibat capsules/pellets (Bylvay®).

The Evolving Story of JAK Inhibitors for Treating Alopecia Areata: A Review of Current Progress and Future Directions

Oral JAK inhibitors are now the first-line treatment for advanced alopecia areata, surpassing topical JAK inhibitors. Baricitinib's FDA approval in 2022 was a significant milestone. More JAK inhibitors are being studied, and additional medications may gain approval soon. JAK inhibitors show promise for alopecia areata with a generally good safety profile, but long-term data is lacking.

Utilization of Topical Ruxolitinib in Dermatology: A Review

Topical ruxolitinib shows promise in various dermatological conditions, including atopic dermatitis, vitiligo, psoriasis, and lichen planus, with a favorable safety profile compared to oral JAK inhibitors. However, its effectiveness in alopecia areata remains inconclusive.

Update on Drugs & Devices: May – June 2023

Update on Targeted alkali thermolysis (TAT) technology (Brella™ 3-miniute SweatControl Patch™), Retifanlimab-dlwr for IV infusion (Zynyz™), Spesolimab IV for IV infusion (Spevigo®) and CRISPR-based therapy (NTLA-2002).

Review of Dermato-Surgery Peri-Procedure Care Promoting Wound Healing

Peri-procedural measures in dermato-surgery depend on patient factors and procedure type. Standardized guidelines support healthcare providers in optimizing outcomes, preventing infection, and reducing recovery time. Research is needed to evaluate purpose-designed moisturizers for post-procedural application and improving patient outcomes.

Antibiotic Resistance in Dermatology Part 2: Combating Resistance

The proper and suitable application of antibiotics is crucial in maintaining their effectiveness amidst growing antibiotic resistance. Nevertheless, it is essential for prescribing practitioners to have a heightened understanding of resistance causes and strategies to counteract them.

Chlormethine Gel for the Treatment of Mycosis Fungoides (Cutaneous T-cell Lymphoma) in Canada

Chlormethine gel, a topical antineoplastic agent, has shown safety and efficacy in phase II trials and real-world data for treating adult Mycosis Fungoides patients. Despite potential skin-related side effects, chlormethine gel offers a convenient, skin-directed treatment for stage IA and IB MF-CTCL, addressing an unmet need in Canada.

Update on Drugs & Devices: March – April 2023

Update on Abrocitinib tablet (Cibinqo®), Lanadelumab-flyo SC injection (Takhzyro®), Berdazimer gel, 10.3% (SB206), Methotrexate oral solution, 2 mg/mL (Jylamvo®), and Anticancer plasmid DNA vaccine (ITI-3000).

Understanding Psoriasis: Insights from Les Journées Dermatologiques de Paris

Drs. Joël Claveau & Julien Ringuet, two Canadian dermatologists with prominent clinical and research practices, attended the Les Journées Dermatologiques de Paris conference in Nov-Dec 2022, with a focus on presentations and posters about psoriasis. This article reviews key insights they obtained at the meeting.

Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults

Tralokinumab is an effective and safe treatment for adult patients with moderate-to-severe AD. It may be used alone or in combination with TCS. This biologic can be considered first-line treatment after failure of or intolerance to topical therapies.

Antibiotic Resistance in Dermatology Part 1: Mechanisms of Resistance

Awareness of the molecular mechanisms of antibiotic resistance among bacteria is necessary to understand the etiology of antibiotic resistance in dermatology at the most basic level.

Update on Drugs & Devices: January – February 2023

Update covering: Deucravacitinib tablets (Sotyktu™), mRNA vaccine + pembrolizumab IV combination therapy (mRNA-4157/V940 + Keytruda®), Adalimumab-aacf SC injection (Idacio®), Dupilumab for SC injection (Dupixent®), and Spesolimab IV injection (Spevigo®).

POPULAR

Advertisement